1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
https://www.hikma.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 8,700
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Engineer Said Samih Taleb Darwazah | Exec. Chairman & CEO | 2.71M | N/A | 1957 |
Mr. Mazen Samih Taleb Darwazah | Exec. Vice Chairman & Pres of MENA | 2.11M | N/A | 1958 |
Mr. Khalid Waleed Hosny Al Nabilsi | Chief Financial Officer | N/A | N/A | 1972 |
Mr. Hussein Arkhagha | Company Sec. & Chief Counsel | N/A | N/A | N/A |
Mr. Bassam Wael Rushdi Kanaan CFA, CPA | Exec. VP of Corp. Devel. and M&A | N/A | N/A | 1965 |
Ms. Susan Ringdal | Exec. VP of Strategic Planning & Global Affairs | N/A | N/A | N/A |
Ms. Majda Labadi | Exec. VP of Organisational Devel. | N/A | N/A | N/A |
Mr. Riad Mishlawi | Pres of Injectables | N/A | N/A | N/A |
Mr. Brian Hoffmann | Pres of Generics | N/A | N/A | N/A |
Mr. Samuel Park | Global Head of Intellectual Property (IP) & Gen. Counsel for US | N/A | N/A | N/A |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals PLC’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 1; Compensation: 4.